Douglas B Cines Selected Research

Stroke (Strokes)

1/2019	Release of IL-6 After Stroke Contributes to Impaired Cerebral Autoregulation and Hippocampal Neuronal Necrosis Through NMDA Receptor Activation and Upregulation of ET-1 and JNK.
1/2018	tPA variant tPA-A296-299 Prevents impairment of cerebral autoregulation and necrosis of hippocampal neurons after stroke by inhibiting upregulation of ET-1.
1/2016	Tissue-Type Plasminogen Activator-A296-299 Prevents Impairment of Cerebral Autoregulation After Stroke Through Lipoprotein-Related Receptor-Dependent Increase in cAMP and p38.
2/2014	PAI-1-derived peptide EEIIMD prevents hypoxia/ischemia-induced aggravation of endothelin- and thromboxane-induced cerebrovasoconstriction.
3/2012	RBC-coupled tPA Prevents Whereas tPA Aggravates JNK MAPK-Mediated Impairment of ATP- and Ca-Sensitive K Channel-Mediated Cerebrovasodilation After Cerebral Photothrombosis.
11/2011	Red blood cell-coupled tissue plasminogen activator prevents impairment of cerebral vasodilatory responses through inhibition of c-Jun-N-terminal kinase and potentiation of p38 mitogen-activated protein kinase after cerebral photothrombosis in the newborn pig.
2/2011	tPA contributes to impairment of ATP and Ca sensitive K channel mediated cerebrovasodilation after hypoxia/ischemia through upregulation of ERK MAPK.
8/2010	Novel plasminogen activator inhibitor-1-derived peptide protects against impairment of cerebrovasodilation after photothrombosis through inhibition of JNK MAPK.
7/2010	PAI-1-derived peptide EEIIMD prevents impairment of cerebrovasodilation by augmenting p38 MAPK upregulation after cerebral hypoxia/ischemia.
8/2009	Red blood cells-coupled tPA prevents impairment of cerebral vasodilatory responses and tissue injury in pediatric cerebral hypoxia/ischemia through inhibition of ERK MAPK activation.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Douglas B Cines Research Topics

Disease

53	Thrombocytopenia (Thrombopenia) 01/2023 - 02/2002
44	Thrombosis (Thrombus) 12/2023 - 02/2002
31	Idiopathic Thrombocytopenic Purpura (Thrombocytopenic Purpura, Autoimmune) 10/2023 - 08/2002
24	Hemorrhage 10/2023 - 08/2003
18	Inflammation (Inflammations) 01/2022 - 05/2003
11	Stroke (Strokes) 01/2019 - 09/2006
10	Infections 01/2021 - 12/2003
10	Ischemia 08/2017 - 02/2008
9	Hypotension (Low Blood Pressure) 01/2018 - 09/2008
8	Hypoxia (Hypoxemia) 09/2023 - 10/2005
8	Neoplasms (Cancer) 12/2017 - 05/2003
8	Acute Lung Injury 02/2017 - 10/2006
8	Traumatic Brain Injuries (Traumatic Brain Injury) 04/2015 - 09/2004
6	Brain Injuries (Brain Injury) 09/2011 - 09/2004
5	Atherosclerosis 01/2020 - 05/2002
4	Sepsis (Septicemia) 11/2023 - 10/2012
4	COVID-19 01/2022 - 05/2020
4	Thrombotic Thrombocytopenic Purpura 12/2017 - 11/2012
4	Vascular System Injuries 05/2015 - 06/2004
4	Hypercapnia 11/2011 - 09/2008
3	Carcinogenesis 09/2023 - 03/2007
3	Thromboembolism 11/2020 - 11/2016
3	Hemolysis 01/2020 - 06/2007
3	Venous Thromboembolism 01/2020 - 02/2012
3	Pre-Eclampsia (Preeclampsia) 01/2020 - 11/2017
3	Ischemic Stroke 01/2019 - 04/2010
3	Thrombotic Microangiopathies 12/2017 - 09/2013
3	Purpura 01/2016 - 11/2008
3	acquired Thrombotic thrombocytopenic purpura 01/2016 - 01/2016
3	Brain Hypoxia-Ischemia (Hypoxia Ischemia, Brain) 07/2010 - 10/2005
3	Lung Injury 06/2010 - 05/2003
3	Neoplasm Metastasis (Metastasis) 03/2007 - 02/2006
3	Pathologic Processes 10/2006 - 10/2002
2	Vascular Remodeling 09/2023 - 03/2006
2	Pulmonary Hypertension 09/2023 - 01/2017
2	Disease Progression 01/2021 - 07/2010
2	Autoimmune Hemolytic Anemia (Cold Agglutinin Disease) 01/2020 - 01/2013
2	Antiphospholipid Syndrome (Antiphospholipid Antibody Syndrome) 01/2020 - 11/2012
2	Necrosis 01/2019 - 01/2018
2	Venous Thrombosis (Deep-Vein Thrombosis) 01/2018 - 08/2003
2	Atypical Hemolytic Uremic Syndrome 12/2017 - 11/2017
2	Reperfusion Injury 01/2017 - 08/2009

Drug/Important Bio-Agent (IBA)

41	Heparin (Liquaemin)FDA LinkGeneric 01/2023 - 02/2002
26	Platelet Factor 4IBA 01/2023 - 02/2002
24	Inosine Triphosphate (ITP)IBA 10/2023 - 08/2002
24	AntibodiesIBA 01/2023 - 02/2002
22	Urokinase-Type Plasminogen Activator (Urokinase)FDA Link 12/2017 - 10/2002
19	Plasminogen Activators (Plasminogen Activator)IBA 09/2023 - 10/2002
18	Tissue Plasminogen Activator (Alteplase)FDA Link 01/2019 - 09/2004
12	Proteins (Proteins, Gene)FDA Link 08/2017 - 10/2002
10	AutoantibodiesIBA 01/2016 - 08/2002
9	Antigen-Antibody Complex (Immune Complex)IBA 01/2023 - 01/2009
9	FibrinIBA 01/2019 - 08/2003
8	AntigensIBA 01/2023 - 02/2007
7	Immunoglobulin G (IgG)IBA 01/2023 - 02/2007
6	N-Methylaspartate (NMDA)IBA 01/2019 - 05/2005
6	GlycosaminoglycansIBA 07/2016 - 06/2004
5	AnticoagulantsIBA 01/2023 - 11/2004
5	ChemokinesIBA 11/2022 - 06/2004
5	alpha-DefensinsIBA 10/2022 - 08/2004
5	Monoclonal AntibodiesIBA 01/2022 - 02/2002
5	Phosphotransferases (Kinase)IBA 01/2018 - 03/2009
5	Thrombopoietin ReceptorsIBA 12/2017 - 11/2008
5	Peptides (Polypeptides)IBA 01/2016 - 08/2004
5	von Willebrand FactorIBA 01/2016 - 12/2011
5	Urokinase Plasminogen Activator ReceptorsIBA 02/2009 - 05/2003
4	Complement System Proteins (Complement)IBA 11/2022 - 09/2013
4	Interleukin-6 (Interleukin 6)IBA 01/2022 - 10/2006
4	Mitogen-Activated Protein KinasesIBA 01/2019 - 03/2009
4	N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA 01/2019 - 11/2013
4	Rituximab (Mabthera)FDA Link 12/2017 - 08/2012
4	ThrombomodulinIBA 08/2017 - 08/2009
4	Thrombin FDA Link 11/2016 - 02/2007
4	thiamine triphosphorate (TTP)IBA 01/2016 - 05/2015
3	Plasminogen Activator Inhibitor 1IBA 09/2023 - 05/2003
3	DefensinsIBA 01/2021 - 02/2016
3	oxidized low density lipoproteinIBA 01/2020 - 05/2002
3	Endothelin-1 (Endothelin 1)IBA 01/2019 - 02/2014
3	Thromboplastin (Tissue Factor)IBA 08/2017 - 02/2008
3	romiplostim FDA Link 01/2017 - 11/2008
3	ProdrugsIBA 02/2016 - 11/2009
3	Hemostatics (Antihemorrhagics)IBA 02/2016 - 08/2003
3	Glutamic Acid (Glutamate)FDA Link 01/2016 - 03/2011
3	PlasminogenIBA 01/2016 - 05/2003
3	Protamines (Protamine Sulfate)FDA Link 04/2013 - 11/2004
3	Plasminogen InactivatorsIBA 09/2011 - 09/2006
2	Glycoproteins (Glycoprotein)IBA 12/2023 - 09/2007
2	VaccinesIBA 01/2023 - 01/2023
2	polyanionsIBA 01/2023 - 01/2020
2	butyl phosphorotrithioate (DEF)IBA 01/2022 - 02/2016
2	LipidsIBA 01/2020 - 02/2016
2	EnzymesIBA 01/2020 - 11/2012
2	CholesterolIBA 01/2020 - 02/2016
2	cyclo(Trp-Asp-Pro-Val-Leu)IBA 01/2019 - 01/2018
2	Biomarkers (Surrogate Marker)IBA 12/2018 - 09/2014
2	anticomplementIBA 12/2017 - 11/2017
2	Protein CIBA 01/2017 - 09/2011

Therapy/Procedure

20	Therapeutics 01/2023 - 02/2002
6	Splenectomy 10/2022 - 01/2004
3	Thrombolytic Therapy 01/2021 - 08/2009